SNIPR enrolls first patient in Phase 2 portion of SNIPR001 trial, expanding study to 66 patientsCOPENHAGEN, Denmark, Sept. 17, 2026 (GLOBE NEWSWIRE) -- SNIPR today announced that the first patient has been enrolled in Part 2 of the Phase 1b/2a clinical trial of SNIPR001 (NCT06938867), the Company's lead CRISPR-armed phage therapeutic candidate for the prevention of Escherichia coli bloodstream infections in patients undergoing hematopoietic stem cell transplantation. The study will enroll an additional 42 patients, bringing the total study population to 66 patients.
Expanded Access Case Report of SNIPR001, an Engineered CRISPR Medicine, in Rare Intracellular E. coli Disease Published in Clinical Infectious DiseasesCOPENHAGEN, Denmark, Aug. 12, 2026 (GLOBE NEWSWIRE) -- SNIPR today announced the publication of a peer-reviewed expanded access case report in Clinical Infectious Diseases https://doi.org/10.1093/cid/ciag446 describing the use of SNIPR001 in a kidney transplant recipient with progressive, multidrug-resistant Escherichia coli malakoplakia, a rare disease characterized by intracellular bacterial persistence.
SNIPR announces Publication of Final Positive Phase 1 Results for SNIPR001 in The Lancet MicrobeCOPENHAGEN, Denmark, March 03, 2026 (GLOBE NEWSWIRE) -- SNIPR Biome ApS (“SNIPR”), the company pioneering CRISPR-based microbial gene therapy, today announced publication of the final results from its first-in-human Phase 1 clinical trial of SNIPR001 in The Lancet Microbe. SNIPR001 is a novel CRISPR–Cas-armed bacteriophage therapeutic designed to selectively reduce colonization of Escherichia coli (E. coli) in the gastrointestinal tract, including antibiotic-resistant strains, while preserving the broader commensal microbiota.
SNIPR BIOME Raises EUR 35 Million Series B Financing to Advance CRISPR-Medicines Targeting Antimicrobial ResistanceCOPENHAGEN, Denmark, Aug. 07, 2025 (GLOBE NEWSWIRE) -- SNIPR Biome ApS (“SNIPR”), the company pioneering the development of microbial CRISPR-medicine, today announced the close of a EUR 35 million Series B raise with funding from new investors the Cystic Fibrosis Foundation and the German Federal Agency for Breakthrough Innovation (SPRIN-D) as well as existing investors Lundbeckfonden BioCapital, North-East Family Office and Wellington Partners.
SNIPR BIOME Announces First Patient Dosed in its Phase 1b Clinical Trial of SNIPR001 in Patients with Hematological CancerCOPENHAGEN, Denmark, June 12, 2025 (GLOBE NEWSWIRE) -- SNIPR Biome ApS (“SNIPR”), the company pioneering the development of precision medicines using CRISPR technology for microbial gene therapy, today announced that the first patient has been dosed in its Phase 1b study of SNIPR001 in patients with hematological cancer who are undergoing hematopoietic stem-cell transplantation (HSCT).
SNIPR Biome Strengthens IP Portfolio with Patent Granted for a Novel CRISPR-Cas SystemCOPENHAGEN, Denmark, Feb. 24, 2025 (GLOBE NEWSWIRE) -- SNIPR BIOME ApS (“SNIPR” or “the Company”), a clinical stage biotech company pioneering CRISPR-based therapies, today announces grant of patent EP4392563B on February 24th 2025 by the European Patent Office protecting the newly-discovered and characterised CRISPR-CasS™ system. This system and its uses do not rely on Cas9 or Cas3. The patent covers use of the new CasS system in both prokaryotic and eukaryotic cells, as well as when fused to effector domains conferring additional functionality, such as base editors and nuclease domains. Commercial licenses are available.
SNIPR Biome receives funding for the development of CRISPR-medicines to improve Environmental Enteric Dysfunction (EED) in pregnant womenSNIPR BIOME receives funding from the Bill & Melinda Gates Foundation to accelerate the development of SNIPR Biome's microbial gene therapy platform to improve Environmental Enteric Dysfunction (EED) in pregnant women from low- and middle-income countries (LMICs).
